The Asia Pacific epilepsy market was valued at US$ 2,200.92 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to register a CAGR of 4.6% from 2022 to 2030.
Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. In 2023, on the Purple Day of Epilepsy, Aster Prime Hospitals in Hyderabad (India), in collaboration with the Walkers Association of Krishna Kant Park, held an awareness activity. One hundred fifty participants in total, including walkers and yoga practitioners, attended this session. Additionally, in order to improve the quality of life for Australians living with epilepsy, Epilepsy Action Australia offers a variety of tools and services aimed at raising awareness, educating, and equipping individuals with the necessary skills. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.
The Asia Pacific epilepsy market is analyzed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively.
The Asia Pacific epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.
Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.
In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.
By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.
Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.
In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.
By country, the Asia Pacific epilepsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy market share in 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Asia Pacific epilepsy market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 2,200.92 Million |
| Market Size by 2030 | US$ 3,143.44 Million |
| CAGR (2022 - 2030) | 4.6% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Epilepsy Market is valued at US$ 2,200.92 Million in 2022, it is projected to reach US$ 3,143.44 Million by 2030.
As per our report Asia Pacific Epilepsy Market, the market size is valued at US$ 2,200.92 Million in 2022, projecting it to reach US$ 3,143.44 Million by 2030. This translates to a CAGR of approximately 4.6% during the forecast period.
The Asia Pacific Epilepsy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Epilepsy Market report:
The Asia Pacific Epilepsy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Epilepsy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Epilepsy Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Epilepsy Market
